Page 13 - Pagetit

NEUROSCIENCE OF PSYCHOACTVE SUBSTANCE USE AND DEPENDENCE

School of Public Health, Boston, MA, USA; Andrey Ryabinin, Oregon Health
Science University, Portland, OR, USA; Allison Smith, Department of
Population and International Health, Harvard University School of Public
Health, Boston, MA, USA; Rachel Tyndale, Department of Pharmacology,
University of Toronto, Toronto, Ontario, Canada; Claude Uehlinger,
Psychosocial Centre of Fribourg, Fribourg, Switzerland; Franco Vaccarino,
Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Frank
Vocci, National Institute on Drug Abuse, Bethesda, MD, USA; David Walsh,
National Institute on Media and the Family, Minneapolis, MN, USA.
Thanks are also due to the international scientific organizations that
provided documents reflecting their views on research on and treatment of
substance dependence. Notable among these are the College on Problems of
Drug Dependence (CPDD) and the International Society of Addiction
Medicine (ISAM).
Many individuals participated in the various consultations held to discuss
the project. The first such consultation which took place in New Orleans, LA,
USA, in 2000 was attended by experts representing several international
organizations, including the CPDD, the International Society for Biomedical
Research on Alcoholism (ISBRA), the National Institute on Drug Abuse
(NIDA), the National Institute of Mental Health (NIMH) and some key
scientists in the field (see list below). The second consultation was held in
Mexico in June 2002 during which a draft report was presented and discussed
extensively. Thanks are due to the following for their various contributions
to the report:
Hector Velasquez Ayala, Faculty of Psychology, Universidad Nacional
Autonoma de Mexico, Mexico City, Mexico; Floyd Bloom, Scripps Research
Institute, La Jolla, CA, USA; Dennis Choi, Department of Neurology,
Washington University School of Medicine, St Louis, MO, USA; Patricia Di
Ciano, University of Cambridge, Cambridge, England; Linda Cottler,
Department of Psychiatry, Washington University, St. Louis, MO, USA; Nady
El-Guebaly, Faculty of Medicine, University of Calgary, Calgary, Alberta,
Canada; Humberto Estanol, National Council Against Addictions of Mexico,
Mexico City, Mexico; Hamid Ghodse, St. George’s Hospital Medical School,
London, UK; Steven Hyman, National Institute of Mental Health, Bethesda,
MD, USA; Mark Jordan, Nyon, Switzerland; Humberto Juarez, National
Council Against Addictions of Mexico, Mexico City, Mexico; Michael Kuhar,
Division of Pharmacology, Emory University, Atlanta, GA, USA; Stan Kutcher,
Canadian Institutes of Health Research, Ottawa, Ontario, Canada; Michel Le
Moal, National Institute of Health and Medical Research, Bordeaux, France;
Scott MacDonald, Centre for Addiction and Mental Health, Toronto, Ontario,
Canada; Guillermina Natera, National Institute of Psychiatry, Mexico City,
Mexico; Raluca Popovici, Pinney Associates, Bethesda, MD, USA; Linda
Porrino, Wake Forest University School of Medicine, NC, Winston-Salem, USA;
David Roberts, Wake Forest University School of Medicine, NC, Winston-
Salem, USA; Robin Room, Centre for Social Research on Alcohol and Drugs,

xii

Pagetit 12 19.1.2004, 12:36